39.4 F
New York
Friday, April 23, 2021

-

Home Business & Finance Univ. of Wash.-spinout Icosavax raises $100M to fund vaccine development technology

Univ. of Wash.-spinout Icosavax raises $100M to fund vaccine development technology

Document Analysis NLP IA

326
WORDS

WORDS
1:37
Reading Time

Reading Time
neutral
sentiment

Sentiment0.069178628389155
objective
redaction

Subjectivity0.41846092503987
it's an affirmation
Affirmation0.61486486486486

Highlights

RELEVANT
FREQ, RAKE or TFIDF
Entity
ORG
Entity
PERSON
Entity
PRODUCT
Entity
OTHER
Key Concepts (and relevance score)

Summary (IA Generated)

Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design.

The startup creates computer-designed, virus-like particles that are used in vaccines to trigger immune responses.

The new funding follows a $51 million round in October 2019.

“Based on preclinical data, we believe our vaccine candidates could offer significant protection against leading viral causes of pneumonia in older adults where no licensed vaccines currently exist,” said Icosavax CEO Adam Simpson, regarding the RSV and hMPV vaccines.

The company launched its COVID program in October, supported in part by $10 million from the Bill & Melinda Gates Foundation.

Strong ties to the Institute for Protein Design: The company is a spinout from the University of Washington’s Institute for Protein Design (IPD).


131FansLike
3FollowersFollow
16FollowersFollow